Akers Biosciences, Inc. Directorate Change - Form 8-K Filing (6181A)
September 13 2018 - 1:01AM
UK Regulatory
TIDMAKR
RNS Number : 6181A
Akers Biosciences, Inc.
13 September 2018
September 13, 2018
Akers Biosciences, Inc.
Directorate Change - Form 8-K Filing
Akers Biosciences, Inc. (NASDAQ: AKER) (AIM: AKR.L), ("Akers
Bio" or the "Company"), a developer of rapid health information
technologies, announces that the Company has filed a Form 8-K with
the U.S. Securities and Exchange Commission stating that Joshua
Silverman was appointed as a director of the Company with effect
from 6 September 2018. The following text is extracted from the
Form 8-K:
"Mr. Silverman currently serves as the Managing Member of
Parkfield Funding LLC. Mr. Silverman was the co-founder, and a
Principal and Managing Partner of Iroquois Capital Management, LLC,
an investment advisory firm. Since its inception in 2003 until July
2016, Mr. Silverman served as Co-Chief Investment Officer of
Iroquois. While at Iroquois, he designed and executed complex
transactions, structuring and negotiating investments in both
public and private companies and has often been called upon by the
companies solve inefficiencies as they relate to corporate
structure, cash flow, and management. From 2000 to 2003, Mr.
Silverman served as Co-Chief Investment Officer of Vertical
Ventures, LLC, a merchant bank. Prior to forming Iroquois, Mr.
Silverman was a Director of Joele Frank, a boutique consulting firm
specializing in mergers and acquisitions. Previously, Mr. Silverman
served as Assistant Press Secretary to The President of the United
States. Mr. Silverman currently serves as a director of DropCar,
Inc., Protagenic Therapeutics, Neurotrope, Inc., and TapImmune
Inc., all of which are public companies. He previously served as a
Director of National Holdings Corporation from July 2014 through
August 2016. Mr. Silverman received his B.A. from Lehigh University
in 1992."
The Company's nominated adviser has not yet had an opportunity
to complete necessary due diligence on Mr. Silverman. A further
announcement containing the disclosures required under the AIM
Rules for Companies will be issued when this process has been
completed.
A copy of the Form 8-K is available to view on Akers Bio's
website at www.akersbio.com or on www.sec.gov.
Contacts:
Akers Biosciences, Inc.
John J. Gormally, Chief Executive Officer
Tel. +1 856 848 8698
finnCap (UK Nominated Adviser and Broker)
Adrian Hargrave / Ed Frisby / Scott Mathieson (Corporate
Finance)
Tel. +44 (0)20 7220 0500
Vigo Communications (Global Public Relations)
Ben Simons / Fiona Henson
Tel. +44 (0)20 7390 0231
Email: akers@vigocomms.com
About Akers Biosciences, Inc.
Akers Bio develops, manufactures, and supplies rapid screening
and testing products designed to deliver quicker and more
cost-effective healthcare information to healthcare providers and
consumers. The Company has advanced the science of diagnostics
while responding to major shifts in healthcare through the
development of several proprietary platform technologies. The
Company's state-of-the-art rapid diagnostic assays can be performed
virtually anywhere in minutes when time is of the essence. The
Company has aligned with major healthcare companies and high volume
medical product distributors to maximize product offerings, and to
be a major worldwide competitor in diagnostics.
Additional information on the Company and its products can be
found at www.akersbio.com. Follow us on Twitter @AkersBio.
Cautionary Note Regarding Forward-Looking Statements
Statements contained herein that are not based upon current or
historical fact are forward-looking in nature and constitute
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. Such forward-looking
statements reflect the Company's expectations about its future
operating results, performance and opportunities that involve
substantial risks and uncertainties. Such statements may include,
without limitation, statements with respect to the Company's plans,
compliance with the requirements of various regulatory agencies and
certain NASDAQ Stock Market listing rules, objectives, projections,
expectations and intentions and other statements identified by
words such as "projects," "may," "will," "could," "would," "should,
" "believes," "expects," "anticipates," "estimates," "intends,"
"plans," "potential" or similar expressions, as they relate to the
Company, its subsidiaries, or its management. These statements are
based upon the current beliefs and expectations of the Company's
management and are subject to significant risks and uncertainties,
including those detailed in the Company's filings with the
Securities and Exchange Commission. Actual results, performance,
prospects, and opportunities to may differ materially from those
set forth in, or implied by, the forward-looking statements. These
forward-looking statements involve certain risks and uncertainties
that are subject to change based on various factors (many of which
are beyond the Company's control). The Company undertakes no
obligation to publicly update any forward-looking statements,
whether as a result of new information, future events or otherwise,
except as required by applicable law.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
BOASFUFUEFASEEU
(END) Dow Jones Newswires
September 13, 2018 02:01 ET (06:01 GMT)
Akers Biosciences (LSE:AKR)
Historical Stock Chart
From Apr 2024 to May 2024
Akers Biosciences (LSE:AKR)
Historical Stock Chart
From May 2023 to May 2024